Variation in Medicaid and commercial coverage of cell and gene therapies

• Egile Nagusiak: Molly T. Beinfeld (Egilea), Julia A. Rucker (Egilea), Nola B. Jenkins (Egilea), Lucas A. de Breed (Egilea), James D. Chambers (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Growth in the availability of cell and gene therapies (CGTs) promises significant innovation in the treatment of serious diseases, but the high cost and one-time administration of CGTs has also raised concern about strain on health plan budgets and inequity in access. We used coverage information fr...